Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AO-176 in Advanced Solid Tumors
NCT03834948Phase 2Completed
- Sponsor
- Arch Oncology
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of AO-176 in epithelial ovarian carcinoma (EOC), endometrial carcinoma, castration-resistant prostate cancer (CRPC) and 6 more (6 arms), sponsored by Arch Oncology. Primary endpoints: Safety of AO-176 assessed by adverse events and laboratory abnormalities up to 12 months, Safety of AO-176 and paclitaxel assessed by adverse events and laboratory abnormalities up to 12 months and 1 more. Started Feb 2019; status: completed.
02
Drugs
AO-176
03
Conditions
epithelial ovarian carcinoma (EOC)endometrial carcinomacastration-resistant prostate cancer (CRPC)lung adenocarcinoma (LUAD)Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT03834948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834948.